方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 生命质量调整年 (QALY)× | Markov 模型在卫生经济学中的应用× | |
|---|---|---|
| 领域 | 卫生经济学 | 卫生经济学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1985 | 1983 |
| 提出者≠ | Alan Williams (Health Economics Research Centre, Oxford University) | Beck & Pauker (medical decision analysis, Massachusetts General Hospital) |
| 类型 | Method | Method |
| 开创性文献≠ | Kind, P. (1989). The EuroQol instrument: an index of health-related quality of life. In B. Teeling Smith (Ed.), Measuring health: a practical approach. Chichester: Wiley. link ↗ | Beck, J. R., & Pauker, S. G. (1983). The Markov Process in Medical Prognosis. Medical Decision Making, 3(4), 419-458. DOI ↗ |
| 别名≠ | QALY, health utility measure | Markov model, state transition model, cohort simulation |
| 相关 | 5 | 5 |
| 摘要≠ | A QALY measures health benefit as utility weight (0 = death, 1 = perfect health) multiplied by time lived. Developed by Alan Williams in 1985, QALYs enable comparison of disparate health interventions on a common metric. Used globally by health technology assessment bodies—NICE (UK), HAS (France), CADTH (Canada), WHO—to decide which treatments deserve public funding. | A Markov model is a decision-analytic tool that simulates disease progression through defined health states over time, calculating cumulative costs and quality-adjusted life years (QALYs) to enable cost-effectiveness analysis. Developed by Beck and Pauker in 1983, Markov models are now the standard framework for projecting long-term outcomes of health interventions, especially chronic diseases where patients transition between clinical states (treatment response, disease progression, remission, death). Used by health technology assessment bodies and pharmaceutical companies to predict intervention value beyond trial duration. |
| ScholarGate数据集 ↗ |
|
|